199 related articles for article (PubMed ID: 9009086)
21. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia.
Batova A; Diccianni MB; Yu JC; Nobori T; Link MP; Pullen J; Yu AL
Cancer Res; 1997 Mar; 57(5):832-6. PubMed ID: 9041181
[TBL] [Abstract][Full Text] [Related]
22. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia.
Bertin R; Acquaviva C; Mirebeau D; Guidal-Giroux C; Vilmer E; Cavé H
Genes Chromosomes Cancer; 2003 May; 37(1):44-57. PubMed ID: 12661005
[TBL] [Abstract][Full Text] [Related]
23. Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China.
Xing EP; Nie Y; Wang LD; Yang GY; Yang CS
Carcinogenesis; 1999 Jan; 20(1):77-84. PubMed ID: 9934853
[TBL] [Abstract][Full Text] [Related]
24. Different patterns of homozygous p16INK4A and p15INK4B deletions in childhood acute lymphoblastic leukemias containing distinct E2A translocations.
Maloney KW; McGavran L; Odom LF; Hunger SP
Leukemia; 1998 Sep; 12(9):1417-21. PubMed ID: 9737691
[TBL] [Abstract][Full Text] [Related]
25. Frequent allelic loss on chromosome 9 in hepatocellular carcinoma.
Liew CT; Li HM; Lo KW; Leow CK; Lau WY; Hin LY; Lim BK; Lai PB; Chan JY; Wang XQ; Wu S; Lee JC
Int J Cancer; 1999 May; 81(3):319-24. PubMed ID: 10209942
[TBL] [Abstract][Full Text] [Related]
26. Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias.
Hayette S; Thomas X; Bertrand Y; Tigaud I; Callanan M; Thiebaut A; Charrin C; Archimbaud E; Magaud JP; Rimokh R
Leukemia; 1997 Oct; 11(10):1696-9. PubMed ID: 9324291
[TBL] [Abstract][Full Text] [Related]
27. Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas.
Tahara H; Smith AP; Gaz RD; Arnold A
J Clin Endocrinol Metab; 1996 Oct; 81(10):3663-7. PubMed ID: 8855819
[TBL] [Abstract][Full Text] [Related]
28. Codeletion of p15 and p16 in primary malignant mesothelioma.
Xio S; Li D; Vijg J; Sugarbaker DJ; Corson JM; Fletcher JA
Oncogene; 1995 Aug; 11(3):511-5. PubMed ID: 7630635
[TBL] [Abstract][Full Text] [Related]
29. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies.
Dreyling MH; Bohlander SK; Le Beau MM; Olopade OI
Blood; 1995 Sep; 86(5):1931-8. PubMed ID: 7544647
[TBL] [Abstract][Full Text] [Related]
30. Recent progress in molecular mechanisms of leukemogenesis: the cyclin-dependent kinase 4-inhibitor gene in human leukemias.
Hirai H; Ogawa S; Hangaishi A; Takahashi T; Kurokawa M; Mitani K; Ueda R; Yazaki Y
Leukemia; 1997 Apr; 11 Suppl 3():358-60. PubMed ID: 9209389
[TBL] [Abstract][Full Text] [Related]
31. Homozygous deletions of cyclin-dependent kinase inhibitor genes, p16(INK4A) and p18, in childhood T cell lineage acute lymphoblastic leukemias.
Iolascon A; Faienza MF; Coppola B; della Ragione F; Schettini F; Biondi A
Leukemia; 1996 Feb; 10(2):255-60. PubMed ID: 8637234
[TBL] [Abstract][Full Text] [Related]
32. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
[TBL] [Abstract][Full Text] [Related]
33. Alterations of p16 and p15 genes in acute leukemia with MLL gene rearrangements and their correlation with clinical features.
Ohnishi H; Guo SX; Ida K; Taki T; Naritaka S; Bessho F; Yanagisawa M; Hanada R; Eguchi M; Kamada N; Kita K; Yamamori S; Hayashi Y
Leukemia; 1997 Dec; 11(12):2120-4. PubMed ID: 9447829
[TBL] [Abstract][Full Text] [Related]
34. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.
Williamson MP; Elder PA; Shaw ME; Devlin J; Knowles MA
Hum Mol Genet; 1995 Sep; 4(9):1569-77. PubMed ID: 8541841
[TBL] [Abstract][Full Text] [Related]
35. Deletion and differential expression of p16INK4a in mouse lung tumors.
Belinsky SA; Swafford DS; Middleton SK; Kennedy CH; Tesfaigzi J
Carcinogenesis; 1997 Jan; 18(1):115-20. PubMed ID: 9054597
[TBL] [Abstract][Full Text] [Related]
36. Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors.
Lubomierski N; Kersting M; Bert T; Muench K; Wulbrand U; Schuermann M; Bartsch D; Simon B
Cancer Res; 2001 Aug; 61(15):5905-10. PubMed ID: 11479232
[TBL] [Abstract][Full Text] [Related]
37. Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias.
Nakamaki T; Kawamata N; Schwaller J; Tobler A; Fey M; Pakkala S; Lee YY; Kim BK; Fukuchi K; Tsuruoka N
Br J Haematol; 1995 Sep; 91(1):139-49. PubMed ID: 7577621
[TBL] [Abstract][Full Text] [Related]
38. Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer.
Heidenreich B; Heidenreich A; Sesterhenn A; Srivastava S; Moul JW; Sesterhenn IA
Eur Urol; 2000 Oct; 38(4):475-82. PubMed ID: 11025389
[TBL] [Abstract][Full Text] [Related]
39. Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes.
Farrell WE; Simpson DJ; Bicknell JE; Talbot AJ; Bates AS; Clayton RN
Cancer Res; 1997 Jul; 57(13):2703-9. PubMed ID: 9205080
[TBL] [Abstract][Full Text] [Related]
40. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population.
Biden K; Young J; Buttenshaw R; Searle J; Cooksley G; Xu DB; Leggett B
Hepatology; 1997 Mar; 25(3):593-7. PubMed ID: 9049204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
